Elicera Therapeutics AB (OSTO:ELIC) Debt-to-Asset : 0.00 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elicera Therapeutics AB Debt-to-Asset?

Elicera Therapeutics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Elicera Therapeutics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was kr0.00 Mil. Elicera Therapeutics AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was kr33.86 Mil. Elicera Therapeutics AB's debt to asset for the quarter that ended in Jun. 2024 was 0.00.

Elicera Therapeutics AB Debt-to-Asset Historical Data

The historical data trend for Elicera Therapeutics AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicera Therapeutics AB Debt-to-Asset Chart

Elicera Therapeutics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Elicera Therapeutics AB Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial														-	-	-	-	-

Competitive Comparison of Elicera Therapeutics AB's Debt-to-Asset

For the Biotechnology subindustry, Elicera Therapeutics AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicera Therapeutics AB's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicera Therapeutics AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Elicera Therapeutics AB's Debt-to-Asset falls into.

Elicera Therapeutics AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Elicera Therapeutics AB's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	30.18
	=	0.00

Elicera Therapeutics AB's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	33.86
	=	0.00

Elicera Therapeutics AB (OSTO:ELIC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Elicera Therapeutics AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Elicera Therapeutics AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicera Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicera Therapeutics AB (OSTO:ELIC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Massans gata 10, World Trade Center Goteborg, 7th Floor, Goteborg, SWE, SE-412 51

Website

https://www.elicera.com

Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.

Elicera Therapeutics AB Headlines

No Headlines